The Ikaros zinc finger transcription factor Aiolos as a novel regulator of T cell migration

• Published in: The Journal of immunology (1950) 2023-05, Vol.210 (1_Supplement), p.243-243.21
• Main Authors: Leonard, Melissa, Read, Kaitlin A, Jones, Devin M, Pokhrel, Srijana, Warren, Robert T, Oestreich, Kenneth J
• Format: Article
• Language: English
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.210.Supp.243.21

Chemokine signaling is an integral component of lymphocyte migration, activation, and survival. The chemokine receptor CXCR3 is highly expressed on CD4 +T helper 1 (T H1) cells, which play a critical role in the adaptive immune response against intracellular pathogens. While CXCR3 helps direct T H1 cells to sites of inflammation or infection, it has also been implicated in a multitude of autoimmune diseases and cancers. Thus, understanding the molecular mechanisms that regulate CD4 +T cell migration is imperative for preventing immunopathology. Here, we identify the Ikaros zinc finger (IkZF) transcription factor Aiolos (IkZF3) as a positive regulator of CXCR3 expression in CD4 +T cells in a murine influenza model. Initially, we show decreased numbers of Aiolos-deficient antigen-specific CD4 +T cells in the lung, which correlates with decreased CXCR3 expression. RNA-seq and ATAC-seq analyses of in vitro-generated WT and Ikzf3 −/−T H1 cells revealed decreased Cxcr3 transcript and reduced chromatin accessibility at regulatory regions of Cxcr3 in the absence of Aiolos, respectively. Collectively, these data imply a novel role for Aiolos in positively regulating CXCR3 expression in T H1 cells. Given these findings, we seek to define the functional effects of Aiolos deficiency on T cell migration and the molecular mechanism(s) by which Aiolos directly and/or indirectly regulates migration. Future work is aimed at determining whether Aiolos affects CXCR3 expression through direct association or indirectly via impacts on other factors. K. J. O. is supported by a grant from The National Institutes of Health (NIH) AI134972, as well as from The Ohio State University College of Medicine and The Ohio State University Comprehensive Cancer Center.